| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/17/2013 | WO2013006972A1 Novel anti-cancer isocarbostyril alkaloid conjugates |
| 01/17/2013 | WO2013006971A1 Sulfur-containing compounds as anti-proliferative agents |
| 01/17/2013 | WO2013006958A1 Radiolabelled rotenone derivatives and their use in spect imaging |
| 01/17/2013 | WO2013006906A1 Dermatan sulphate, pharmaceutical compositions and process for producing same |
| 01/17/2013 | WO2012162307A3 Crosslinked polymer nano-assemblies and uses thereof |
| 01/17/2013 | WO2012161539A3 Sirna for inhibiting the expression of bhrf1 and composition comprising same |
| 01/17/2013 | WO2012161518A3 Novel thiourea derivatives as activators of rorα and pharmaceutical composition containing same |
| 01/17/2013 | WO2012161489A3 Patch containing rivastigmine |
| 01/17/2013 | WO2012160180A3 Pharmaceutical composition for administration to nails |
| 01/17/2013 | WO2012160179A3 Topical pharmaceutical composition based on semifluorinated alkanes |
| 01/17/2013 | WO2012160051A3 Wet granulation methods of cetyl myristate and/or cetyl palmitate |
| 01/17/2013 | WO2012160050A3 Particle size distribution of cetyl myristate and/or cetyl palmitate |
| 01/17/2013 | WO2012159593A3 A combined oral formulation with controlled release of acetylsalicylic acid and a method for the preparation |
| 01/17/2013 | WO2012158866A9 Treatment of autoimmune disorders and infections using antagonists of sgk1 activity |
| 01/17/2013 | WO2012158312A9 Skin and hair regeneration using polysaccharide-based hydrogels |
| 01/17/2013 | WO2012157980A3 Manufacturing method of azilsartan |
| 01/17/2013 | WO2012157977A3 Manufacturing method of heterocyclic compound |
| 01/17/2013 | WO2012156998A3 Amorphous mirabegron and processes for crystal forms of mirabegron |
| 01/17/2013 | WO2012151039A3 Compositions and methods for detecting mycobacterium |
| 01/17/2013 | WO2012149566A3 Anti-hiv group i introns and a uses thereof in treating hiv infections |
| 01/17/2013 | WO2012149478A3 Agents useful for treating friedreich's ataxia and other neurodegenerative diseases |
| 01/17/2013 | WO2012149454A3 Tolerogenic synthetic nanocarriers coupled to cd1d-restricted antigens and methods of use |
| 01/17/2013 | WO2012149406A3 Assessing and treating humans with long qt syndrome |
| 01/17/2013 | WO2012148927A3 Impaired energy processing disorders and mitochondrial deficiency |
| 01/17/2013 | WO2012148926A3 Neurodegenerative disorders and muscle diseases implicating pufas |
| 01/17/2013 | WO2012148225A3 Sustained-release pharmaceutical composition comprising donepezil or pharmaceutically acceptable salt thereof having improved dissolution stability and method for manufacturing the same |
| 01/17/2013 | WO2012146724A3 Novel rock inhibitors |
| 01/17/2013 | WO2012145582A3 Methods and compositions for the specific inhibitions of egfr by double-stranded rna |
| 01/17/2013 | WO2012145254A9 Methods of using inhibitors of rorϒt to treat disease |
| 01/17/2013 | WO2012142388A3 Methods, compounds and pharmaceutical compositions for treating anxiety and mood disorders |
| 01/17/2013 | WO2012142256A3 Modulators of mitochondrial protein import |
| 01/17/2013 | WO2012142083A3 C1q/tnf-related protein 12 and compositions and methods of using same |
| 01/17/2013 | WO2012135697A3 Novel rho kinase inhibitors and methods of use |
| 01/17/2013 | WO2012135600A4 Gall wasp control agents |
| 01/17/2013 | WO2012129452A3 Propynoic acid carbamoyl methyl-amides and pharmaceutical compositions and methods based thereon |
| 01/17/2013 | WO2012125871A3 Aconitine compounds, compositions, uses, and preparation thereof |
| 01/17/2013 | WO2012122451A3 Polymorphs of maxacalcitol and process for the preparation of maxacalcitol |
| 01/17/2013 | WO2012122165A3 Substituted n-aryl pyridinones |
| 01/17/2013 | WO2012088264A3 Purified cardiogenin isomer and related methods |
| 01/17/2013 | WO2012068412A3 Method and compositions for treatment of stat3-responsive cancers and/or renal cancer |
| 01/17/2013 | WO2012068234A3 Antiviral compounds |
| 01/17/2013 | WO2011157908A8 Use of the combination of an inhibitor of the if current of the sinoatrial node and an inhibitor of the angiotensin-converting enzyme for treating heart failure |
| 01/17/2013 | WO2011082487A8 Bisphenol derivatives and their use as androgen receptor activity modulators |
| 01/17/2013 | WO2010141694A3 Borinic compositions |
| 01/17/2013 | US20130019348 Pesticidal compositions and processes related thereto |
| 01/17/2013 | US20130018431 Method for directed intranasal administration of a composition |
| 01/17/2013 | US20130018343 Lotions Derived From Renewable Resources and Absorbent Articles Comprising Same |
| 01/17/2013 | US20130018336 Novel dressing including a web of microfibers or nanofibers suitable for gelling or solubilizing |
| 01/17/2013 | US20130018335 Novel bandage including agglomerates of particles suitable for rapidly gelling or solubilising |
| 01/17/2013 | US20130018333 Method and system for applying a heated skin treatment spray |
| 01/17/2013 | US20130018299 Nanoshells on polymers |
| 01/17/2013 | US20130018109 Skin and hair treatments |
| 01/17/2013 | US20130018106 Hop acids as a replacement for antibiotics in animal feed |
| 01/17/2013 | US20130018105 Cis, 3,4-dihydroxy-2-(3-methylbutanoyl)-5-(3-methylbutyl)-4-(4-methylpentanoyl)cyclopent-2-en-1-one derivatives, substantially enantiomerically pure compositions and methods |
| 01/17/2013 | US20130018104 Emulsive composition containing dapsone |
| 01/17/2013 | US20130018103 Bifunctional histone deacetylase inhibitors |
| 01/17/2013 | US20130018102 Nutritional supplement for the enhancement of muscle performance and recovery |
| 01/17/2013 | US20130018101 Salts of fenofibric acid and pharmaceutical formulations thereof |
| 01/17/2013 | US20130018100 Tranexamic Acid Formulations |
| 01/17/2013 | US20130018096 Platinum complex with antitumor activity |
| 01/17/2013 | US20130018095 Fumigillol Type Compounds and Methods of Making and Using Same |
| 01/17/2013 | US20130018094 Prophylactic or Therapeutic Agent For Gum Disease or Apical Periodontitis |
| 01/17/2013 | US20130018093 Novel epoprostenol formulation and method of making thereof |
| 01/17/2013 | US20130018092 Treatment for hypoxia |
| 01/17/2013 | US20130018091 Treatment of allodynia and hyperalgesia |
| 01/17/2013 | US20130018090 Low-dose doxepin for treatment of sleep disorders in elderly patients |
| 01/17/2013 | US20130018089 Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides |
| 01/17/2013 | US20130018086 Sirnas targeting exon 10 of pyruvate kinase m2 |
| 01/17/2013 | US20130018085 iRNA Agents Targeting VEGF |
| 01/17/2013 | US20130018084 MICRORNA (miRNA) AND DOWNSTREAM TARGETS FOR DIAGNOSTIC AND THERAPEUTIC PURPOSES |
| 01/17/2013 | US20130018083 Use of sirna targetting sipa1l1 for the reduction of adipogenesis |
| 01/17/2013 | US20130018082 RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING CHEMICALLY MODIFIED SHORT INTERFERING NUCLEIC ACID (siNA) |
| 01/17/2013 | US20130018081 AChE ANTISENSE OLIGONUCLEOTIDE AS AN ANTI-INFLAMMATORY AGENT |
| 01/17/2013 | US20130018080 Compositions comprising amino acids for treating chronic obstructive pulmonary disease |
| 01/17/2013 | US20130018079 Antimicrobial compositions and methods of use thereof |
| 01/17/2013 | US20130018078 Adhesive mixture for transdermal delivery of highly plasticizing drugs |
| 01/17/2013 | US20130018077 Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders |
| 01/17/2013 | US20130018076 Trigonelline as a muscle stimulant |
| 01/17/2013 | US20130018075 Heterocyclic inhibitors of mek and methods of use thereof |
| 01/17/2013 | US20130018074 New compounds |
| 01/17/2013 | US20130018073 Indole derivative |
| 01/17/2013 | US20130018072 Aminopyrazole triazolothiadiazole inhibitors of c-met protein kinase |
| 01/17/2013 | US20130018071 Solid Forms of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| 01/17/2013 | US20130018070 Modulators of cystic fibrosis transmembrane conductance regulator |
| 01/17/2013 | US20130018069 Sustained release delivery systems for the prevention and treatment of head and neck cancers |
| 01/17/2013 | US20130018068 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
| 01/17/2013 | US20130018067 Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/17/2013 | US20130018066 Heterocyclic aspartyl protease inhibitors |
| 01/17/2013 | US20130018065 Processes for the preparation of key intermediate for the synthesis of rosuvastatin or pharmaceutically acceptable salts thereof |
| 01/17/2013 | US20130018064 Amino Heteroaryl Compounds as Beta-Secretase Modulators and Methods of Use |
| 01/17/2013 | US20130018063 Organic compounds |
| 01/17/2013 | US20130018062 Pain therapy with metabolism blocked antifolates |
| 01/17/2013 | US20130018061 Method for Improving Exercise and Recovery From Exercise |
| 01/17/2013 | US20130018060 Inhibitors of bruton's tyrosine kinase |
| 01/17/2013 | US20130018059 Dimethyl sulfoxide (dmso) formulations for treating autism |
| 01/17/2013 | US20130018058 Pharmaceutically acceptable salts of quinolinone compounds having improved pharmaceutical properties |
| 01/17/2013 | US20130018057 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors |
| 01/17/2013 | US20130018056 Method of treatment for mental disorders |
| 01/17/2013 | US20130018055 New aryl-benzocycloalkyl amide derivatives |
| 01/17/2013 | US20130018054 New compounds |